A pharmaceutical company is considering launching a new drug for a rare genetic disorder. Clinical trials have shown that the drug effectively slows the progression of the disorder in 70% of patients. However, the company faces high manufacturing costs for the drug. A company executive argues that despite these costs, the drug will be highly profitable because there is no other effective treatment currently available for this disorder.
Correct: D
The executive's argument is that the drug will be 'highly profitable' despite high manufacturing costs, primarily due to the lack of alternative treatments. While the absence of alternatives allows for a high price, it does not guarantee that patients (or their insurance providers) will be willing *and able* to pay such a high price. For the drug to be highly profitable, the revenue generated must significantly exceed the high manufacturing costs. This revenue depends on both the number of patients and the price they pay. Option D directly addresses this critical link: if patients are not willing or able to pay a high price, then profitability, despite the lack of alternatives, is not guaranteed. Option A (patent protection) is important for *long-term* profitability but not the immediate profitability claim based on lack of alternatives. Option B (ineffective patients) affects overall revenue but not the core pricing strategy. Option C (market size) is a necessary condition for profitability but, like the lack of alternatives, does not by itself guarantee that prices can be set high enough to ensure *high* profitability. Option E (side effects) relates to market adoption, which is essential, but the core issue for profitability given *high costs* is the ability to charge a high enough price.